S. Ozakbas Et Al. , "Real-world safety and patient profile of fingolimod in relapsing-remitting multiple sclerosis: how risky is fingolimod-induced lymphopenia?," 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS , vol.25, Stockholm, Sweden, pp.878-879, 2019
Ozakbas, S. Et Al. 2019. Real-world safety and patient profile of fingolimod in relapsing-remitting multiple sclerosis: how risky is fingolimod-induced lymphopenia?. 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS , (Stockholm, Sweden), 878-879.
Ozakbas, S., Aslan, T., & Baba, C., (2019). Real-world safety and patient profile of fingolimod in relapsing-remitting multiple sclerosis: how risky is fingolimod-induced lymphopenia? . 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS (pp.878-879). Stockholm, Sweden
Ozakbas, S., T. Aslan, And C. Baba. "Real-world safety and patient profile of fingolimod in relapsing-remitting multiple sclerosis: how risky is fingolimod-induced lymphopenia?," 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 2019
Ozakbas, S. Et Al. "Real-world safety and patient profile of fingolimod in relapsing-remitting multiple sclerosis: how risky is fingolimod-induced lymphopenia?." 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS , Stockholm, Sweden, pp.878-879, 2019
Ozakbas, S. Aslan, T. And Baba, C. (2019) . "Real-world safety and patient profile of fingolimod in relapsing-remitting multiple sclerosis: how risky is fingolimod-induced lymphopenia?." 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS , Stockholm, Sweden, pp.878-879.
@conferencepaper{conferencepaper, author={S. Ozakbas Et Al. }, title={Real-world safety and patient profile of fingolimod in relapsing-remitting multiple sclerosis: how risky is fingolimod-induced lymphopenia?}, congress name={35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS}, city={Stockholm}, country={Sweden}, year={2019}, pages={878-879} }